|Bid||2.650 x 1000|
|Ask||3.600 x 1000|
|Day's Range||2.935 - 3.010|
|52 Week Range||2.580 - 5.660|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.36|
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Increase in profitability and industry-beating performance can be essential considerations in a stock for some investors. In this article, I will take a look at Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) trackRead More...
The New Haven, Connecticut-based company said it had a loss of 17 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Corporate restructuring expected to enable Achillion to focus on goal of advancing its clinical and late-stage preclinical portfolio while maintaining a strong balance sheet Joseph Truitt, Chief Operating ...
NEW HAVEN, Conn., Feb. 09, 2018-- Achillion Pharmaceuticals, Inc. announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will participate in a fireside chat at ...
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.
Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).
BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.
NEW HAVEN, Conn., Dec. 20, 2017-- In the news release issued earlier today by Achillion Pharmaceuticals, Inc., please be advised the headline should read "Achillion Initiates Phase I First-In-Human ...
NEW HAVEN, Conn., Dec. 20, 2017-- Achillion Pharmaceuticals, Inc., a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the complement alternative pathway, today announced ...
-Orphan drug designation for the treatment of C3G granted by the U.S. -Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in healthy volunteers–. NEW HAVEN, Conn., Dec. ...
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.
Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.
NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while ...
Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.
Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.
Achillion Pharmaceuticals saw its shares make a handy gain on Thursday after the company announced a secondary offering.
NEW YORK, NY / ACCESSWIRE / November 16, 2017 / U.S. markets dropped sharply Wednesday, with the Dow and S&P 500 posting its largest daily loss since September, as sliding oil prices dragged down the energy ...